Close Menu

NEW YORK (GenomeWeb) – Belgian diagnostics firm OncoDNA said today that it has signed an agreement under which its tumor profiling products and services will be offered in the Russian Federation by Genext.

Under the deal, Genext will market and distribute OncoDNA's OncoDeep solid tumor test; its OncoTrace and OncoSelect liquid biopsy tests; its OncoStrat&Go solid and liquid biopsy combination; and its OncoKDM data interpretation and reporting software.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.